Living Cell Technologies (LHI0) AI Stock Analysis

Living Cell Technologies

(Frankfurt:LHI0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-Free Balance SheetNo reported debt reduces fixed financial obligations and lowers exposure to refinancing or interest-cost pressure. That gives management greater flexibility to allocate available capital toward research and development, while providing some resilience if development timelines extend.

Negative Factors

No Reported RevenueThe absence of reported revenue means the business has not yet demonstrated commercial traction or an operating revenue base. This leaves future funding and value creation dependent on successful program development, regulatory progress, and eventual commercialization rather than established customer demand.

Living Cell Technologies (LHI0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 7.10M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -5.7
Beta (1Y): 3.23
Revenue Growth: ―
EPS Growth: -200.00%
Country: Germany
Employees: 48
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Living Cell Technologies Business Overview & Revenue Model

Company Description

Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily c...

Living Cell Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:LHI0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	64Neutral	AUD 2.94B	-35.83	-10.06%	―	555.67%	49.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CMB	51Neutral	AUD 11.77M	-1.59	-247.44%	―	-4.24%	33.39%
AU:OCC	50Neutral	AUD 149.82M	-10.38	-36.83%	―	51.07%	-47.63%
AU:CYP	42Neutral	AUD 4.02M	-0.31	-617.89%	―	―	13.67%
AU:TRP	32Underperform	AUD 5.06M	-1.07	-52.04%	―	32.22%	-26.53%

* Healthcare Sector Average

Performance Comparison

DE:LHI0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:LHI0	Living Cell Technologies Ltd.	0.01	0.00	0.00%
AU:CYP	Cynata Therapeutics Limited	0.01	-0.22	-94.78%
AU:MSB	Mesoblast Limited	2.26	-0.22	-8.87%
AU:OCC	Orthocell Ltd	0.55	-0.64	-53.78%
AU:TRP	Tissue Repair Ltd	0.10	-0.24	-71.21%
AU:CMB	Regeneus Ltd.	0.40	-0.09	-19.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Living Cell Technologies AI Stock Analysis